NEW YORK (GenomeWeb) – Belgian biopharmaceutical developer UCB announced today that it has acquired Durham, North Carolina-based Element Genomics for $30 million, which will include upfront and short-term success-based milestone payments.

A biotech spinout from Duke University, Element Genomics has developed several technologies to further understand genome structure and functions, such as CRISPR editing technology for genomic and epigenetic regulatory region analysis and modulation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.